Generic Tosymra Availability

Last updated on May 7, 2025.

Tosymra is a brand name of sumatriptan, approved by the FDA in the following formulation(s):

TOSYMRA (sumatriptan - spray;nasal)

• Manufacturer: TONIX MEDS
  Approval date: January 25, 2019
  Strength(s): 10MG/SPRAY ^[RLD]

Is there a generic version of Tosymra available?

No. There is currently no therapeutically equivalent version of Tosymra available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tosymra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Formulations comprising triptan compounds
  Patent 10,603,305
  Issued: March 31, 2020
  Inventor(s): Gandhi Rajesh & Manikonda Sreekanth & Jana Arun & Kunte Sameer Shrinivas
  Assignee(s): Upsher-Smith Laboratories, LLC
  

  The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tvalue of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.

  Patent expiration dates:

  • June 16, 2030
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE
    ✓ 
    Drug product
• Formulations comprising triptan compounds
  Patent 11,337,962
  Issued: May 24, 2022
  Inventor(s): Gandhi; Rajesh et al.
  Assignee(s): Upsher-Smith Laboratories, LLC (Maple Grove, MN)
  

  The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T.sub.max value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T.sub.max substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

  Patent expiration dates:

  • June 16, 2030
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE
    ✓ 
    Drug product
• Formulations comprising triptan compounds
  Patent 12,090,139
  Issued: September 17, 2024
  Inventor(s): Gandhi; Rajesh et al.
  Assignee(s): TONIX MEDICINES, INC. (Chatham, NJ)
  

  The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T.sub.max value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T.sub.max substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

  Patent expiration dates:

  • June 16, 2030
    
    ✓ 
    Drug product
• Alkylglycoside compositions for drug administration
  Patent 8,268,791
  Issued: September 18, 2012
  Inventor(s): Maggio Edward T.
  Assignee(s): Aegis Therapeutics, LLC.
  

  The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

  Patent expiration dates:

  • May 9, 2026
    
    ✓ 
    Drug product
• Compositions for drug administration
  Patent 8,440,631
  Issued: May 14, 2013
  Inventor(s): Maggio Edward T.
  Assignee(s): Aegis Therapeutics, LLC
  

  The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

  Patent expiration dates:

  • May 9, 2026
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE
    ✓ 
    Drug product
• Formulations comprising triptan compounds
  Patent 9,211,282
  Issued: December 15, 2015
  Inventor(s): Gandhi Rajesh & Manikonda Sreekanth & Jana Arun & Kunte Sameer Shrinivas
  Assignee(s): DR. REDDY'S LABORATORIES LTD.
  

  The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tvalue of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.

  Patent expiration dates:

  • July 19, 2031
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE
    ✓ 
    Drug product
• Compositions for drug administration
  Patent 9,283,280
  Issued: March 15, 2016
  Inventor(s): Maggio Edward T.
  Assignee(s): Aegis Therapeutics, LLC
  

  The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

  Patent expiration dates:

  • May 9, 2026
    
    ✓ 
    Drug product
• Formulations comprising triptan compounds
  Patent 9,610,280
  Issued: April 4, 2017
  Inventor(s): Gandhi Rajesh & Manikonda Sreekanth & Jana Arun & Kunte Sameer Shrinivas
  Assignee(s): DR. REDDY'S LABORATORIES LIMITED
  

  The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tvalue of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.

  Patent expiration dates:

  • June 16, 2030
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE
    ✓ 
    Drug product
• Formulations comprising triptan compounds
  Patent 9,974,770
  Issued: May 22, 2018
  Inventor(s): Gandhi Rajesh & Manikonda Sreekanth & Jana Arun & Kunte Sameer Shrinivas
  Assignee(s): DR. REDDY'S LABORATORIES LTD.
  

  The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tvalue of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tsubstantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

  Patent expiration dates:

  • June 16, 2030
    
    ✓ 
    Patent use: ACUTE TREATMENT OF MIGRAINE
    ✓ 
    Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer